跳至主要内容
临床试验/CTRI/2024/07/070172
CTRI/2024/07/070172尚未招募3 期

Evaluation of efficacy of add on oral minocycline in children with Acute Encephalitis Syndrome aged 1 month-18 years: a open-labelled randomized controlled trial (MAES trial)

All India Institute of Medical Sciences1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2024年7月19日最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
130
试验地点
1
主要终点
The primary outcome is change in FSS scale score at 12 weeks as compared to baseline.

研究概览

简要总结

A definitive and dramatic cure is not available for most cases of AES. A significant proportion of patients with AES develop short term and long term adaptive, cognitive and behavioral impairment. Minocycline is a semisynthetic tetracycline, which is safe and approved for human use. It is lipophilic, acts as a neuroprotective agent and in animal models have been shown to be efficacious against reovirus, West Nile virus, HIV and JEV. The hypothesis is Add on oral minocycline being more efficacious in improving the functional status of children aged 1 month to 18 years at 12 weeks as compared to standard treatment alone.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
1.00 Month(s) 至 18.00 Year(s)(—)
性别
All

入选标准

  • 1.Children between age 1 month-18 years of age
  • Presenting to department of pediatrics, AIIMS Rishikesh with a clinical diagnosis of acute encephalitis syndrome
  • Parents willing to comply with the study protocol and follow up.

排除标准

  • Preexisting major chronic systemic illness including cardiovascular, respiratory, gastrointestinal system or chronic renal disease
  • Preexisting developmental delay or intellectual disability
  • Definite diagnosis of neurometabolic or neurodegenerative disease
  • Caregivers not giving informed consent
  • History of allergy to minocycline previously
  • Children in whom Minocycline can’t be administered orally or through nasogastric tube within 72 hours of presenting to our institute due to clinical contraindications.

结局指标

主要结局

The primary outcome is change in FSS scale score at 12 weeks as compared to baseline.

时间窗: baseline and 12 weeks

次要结局

  • change in Glassgow coma scale(day0, day7 and 12 weeks)
  • Change in Paediatric cerebral performance category score(baseline day 7 and day 12)
  • mortality(day 7 and 12 weeks)
  • duration of hospitalisation(12 weeks)
  • PedsQL score(12 weeks)
  • Vineland social maturity score(12 weeks)
  • Childhood Behavioural Checklist(12 weeks)
  • Vineland adaptive behavior score(12 weeks)

研究者

申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Tanisha Gupta

All India institute of Medical Sciences, Rishikesh

研究点 (1)

Loading locations...

相似试验